3Fontbonne AM, Eschwege EM. Insulin and cardiovovascular disease:Plaris Prospective Study[ J ]. Diabets care, 1991,14: 461 - 469.
4Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults[J]. JAMA, 1999,281: 1921 - 1927.
二级参考文献5
1Kameda N, Okuya S, Oka Y. Rosiglitazone (BRL-49653). Nippon Rinsho, 2000, 58 (2): 401-404.
2Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol, 1999, 48 (3): 424-432.
3Wolffenhuttel BH, Gomis R, Squatrito S, et al. Addition of low dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med, 2000, 17 (1) : 40-47.
4Practical Living. Investigational drug shown to lower blood glucose. Diabetes Forecast, 1999, 52 (2): 33-36.
5Adis International Limited. Rosiglitazone: a promising new thiazoledinedione. Drug Ther Bull, 1999, 14 (6): 1-5.
2C. J. J. Tack,M. K. E. Ong,J. A. Lutterman,P. Smits. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone[J] 1998,Diabetologia(5):569～576
